XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Assets:    
Cash and cash equivalents $ 12,945 $ 9,408
Investments 2,778 3,117
Accounts receivable, net 27,276 24,431
Inventories 19,090 17,760
Assets held for sale 908 0
Other current assets 2,636 5,319
Total current assets 65,633 60,035
Long-term investments 21,096 23,025
Property and equipment, net 12,873 12,896
Operating lease right-of-use assets 17,872 19,122
Goodwill 78,150 79,121
Intangible assets, net 24,803 29,052
Separate accounts assets 3,228 5,087
Other assets 4,620 4,714
Total assets 228,275 233,052
Liabilities:    
Accounts payable 14,838 12,544
Pharmacy claims and discounts payable 19,423 17,330
Health care costs payable 10,142 8,678
Policyholders’ funds 1,500 4,301
Accrued expenses 18,745 17,670
Other insurance liabilities 1,089 1,345
Current portion of operating lease liabilities 1,678 1,646
Current portion of long-term debt 1,778 4,205
Liabilities held for sale 228 0
Total current liabilities 69,421 67,719
Long-term operating lease liabilities 16,800 18,177
Long-term debt (1) 50,476 51,971
Deferred income taxes 4,016 6,115
Separate accounts liabilities 3,228 5,087
Other long-term insurance liabilities 5,835 7,235
Other long-term liabilities 6,730 1,907
Total liabilities 156,506 158,211
Commitments and contingencies (Note 17)
Shareholders’ equity:    
Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding 0 0
Common stock, par value $0.01: 3,200 shares authorized; 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and 1,744 shares issued and 1,322 shares outstanding at December 31, 2021 and capital surplus 48,193 47,377
Treasury stock, at cost: 458 and 422 shares at December 31, 2022 and 2021 (31,858) (28,173)
Retained earnings 56,398 54,997
Accumulated other comprehensive income (loss) (1,264) 334
Total CVS Health shareholders’ equity 71,469 74,535
Noncontrolling interests 300 306
Total shareholders’ equity 71,769 74,841
Total liabilities and shareholders’ equity $ 228,275 $ 233,052